Brazil: Farnesene Production DSM Acquires Amyris Brasil

Royal DSM and Amyris announced that they have closed the transaction for the sale of Amyris Brasil to DSM and the establishment of a long-term manufacturing partnership for Amyris’s high-volume products.

Related Vendors

AZO GmbH + Co. KG

Glatt Ingenieurtechnik GmbH

CO.RA. S.r.L.

Amyris Biotechnologies Inc

DSM Biomedical

Heerlen/The Netherlands — The consideration for Amyris Brasil (which owns and operates the Brotas 1 fermentation facility) and intellectual property related to farnesene (a bio-based key intermediate for many applications) is $ 58 million plus an additional value share arrangement over a three-year period amounting to $ 37.5 million (aggregate upfront consideration of $ 96 million). In addition to the consideration upfront, there is potential for a future value share in line with Amyris’ business model.

Brazil: Bio-Based Intermediates

DSM Acquires Brazilian Production Facility from Amyris

With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.

(ID:45070183)